Third-party payers and the cost of biomedical research.
Four principal arguments have been offered in support of requiring public and private third-party payers to help fund medical research: (1) many of the costs associated with clinical trial participation are for routine care that would be reimbursed if delivered outside of a trial; (2) there is a need to promote scientific research and medical progress and lack of coverage is an impediment to enrollment; (3) to cover the costs of trials expands health care and treatment options for the sick; and (4) it is beneficial for private insurers to cover the costs associated with cancer clinical trials because doing so makes such companies more attractive to consumers. Although many see third-party-payer coverage as a victory for patients and for the future of research, requiring coverage of services provided in a trial beyond those that would be provided to a comparable patient outside the research context raises a number of concerns.
Iltis
Ana S
AS
Center for Health Care Ethics, Saint Louis University, St. Louis, MO, USA.
D035843:Biomedical Research / Q000191:economics*; D002986:Clinical Trials as Topic / Q000191:economics* / Q000331:legislation & jurisprudence; D033161:Government Regulation; D017048:Health Care Costs; D006297:Health Services Accessibility / Q000191:economics; D006801:Humans; D019458:Insurance Coverage / Q000191:economics* / Q000941:ethics* / Q000331:legislation & jurisprudence; D007349:Insurance, Health, Reimbursement / Q000191:economics* / Q000941:ethics* / Q000331:legislation & jurisprudence; D037141:Mandatory Programs; D040541:Marketing; D006278:Medicare / Q000331:legislation & jurisprudence; D009369:Neoplasms / Q000628:therapy; D017149:Private Sector; D011640:Public Policy; D017150:Public Sector; D035842:Research Subjects / Q000191:economics*; D012109:Research Support as Topic; D035703:Therapies, Investigational / Q000191:economics; D014481:United States